RECORDATI RARE DISEASES, INC.
BiotechRECORDATI RARE DISEASES, INC. is a biotechnology company with 3 FDA-approved products.
FDA Novel Drug Designations
(2022)See 1 novel approval →
RECORDATI RARE DISEASES, INC.'s Key Drugs
RECORDATI RARE DISEASES, INC.'s core commercial portfolio centers on ENJAYMO, SYLVANT — its most strategically important drugs approved in the last 15 years.
RECORDATI RARE DISEASES, INC.'s Recent FDA Approvals
New NDA/BLA approvals for RECORDATI RARE DISEASES, INC. over the last two years — novel drugs only, excluding generics and label supplements.
RECORDATI RARE DISEASES, INC.'s Therapeutic Areas
Disease areas where RECORDATI RARE DISEASES, INC. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RECORDATI RARE DISEASES, INC. Pipeline Snapshot
Active clinical trials for RECORDATI RARE DISEASES, INC. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ENJAYMO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1983-07-19
- Latest
- 2024-02-08
- Applications
- 3